GTC Biotherapeutics (fka GTCB)

[keitern]

Of all the "reasons", the one I think most likely is that continuing improvements in cell based and other prodution methods over time make GTC's platform less attractive over time. In other words, there is a window for any technology and the longer it takes GTC to advance its own platform, competing technologies are a greater factor by definition. I am not sure how valid this "reason" is however.